Deconstructing schizophrenia for DSM-V: Challenges for clinical and research agendas

Clinical Schizophrenia and Related Psychoses

Volumn 2, Issue 2, 2008, Pages 166-174

  Pierre, Joseph M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diagnosis; DSM; Psychosis; Schizophrenia; Validity

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID;

ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; DELUSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HALLUCINATION; HUMAN; MEDICAL RESEARCH; PATIENT REFERRAL; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; SYMPTOM; VALIDITY;

EID: 48049094352     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.2.2.8     Document Type: Article

References (86)

1. Deconstructing psychosis. 2007 Annual Meeting of the American Psychiatric Association; 2007 May 21; San Diego, CA.
2. Should DSM-V be a schizophrenia-free zone? International Congress on Schizophrenia Research; 2007 March 29; Colorado Springs, CO.
3. Deconstructing/reconstructing schizophrenia for DSM-V. International Congress on Schizophrenia Research; 2007 March 30; Colorado Springs, CO.
4. Zachar P, Kendler KS. Psychiatric disorders: a conceptual taxonomy. Am J Psychiatry 2007;164(4):557-565.
5. Owen MJ, Craddock N, Jablensky A. The genetic deconstruction of psychosis. Schizophr Bull 2007;33(4):905-911.
6. Winterer G, Hariri AR, Goldman D, Weinberger DR. Neuro-imaging and human genetics. Int Rev Neurobiol 2005;67:325-383.
7. Gur RE, Keshavan MS, Lawrie SM. Deconstructing psychosis with human brain imaging. Schizophr Bull 2007;33(4):921-931.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association; 1994.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington (DC): American Psychiatric Association; 1980.
10. Adamson J. An appraisal of the DSM-III system. Can J Psychiatry 1989;34(4):303-310.
11. Yuwiler A. Diagnosis and the hunt for etiology. Biol Psychiatry 1995;37(1):1-3.
12. Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 2003;160(1):4-12.
13. First MB, Pincus HA, Levine JB, Williams JB, Ustun B, Peele R. Clinical utility as a criterion for revising psychiatric diagnoses. Am J Psychiatry 2004;161(6):946-954.
14. Allardyce J, Gaebel W, Zielasek J, van Os J. Deconstructing Psychosis conference February 2006: the validity of schizophrenia and alternative approaches to the classification of psychosis. Schizophr Bull 2007;33(4):863-867.
15. Eaton WW, Romanoski A, Anthony JC, Nestadt G. Screening for psychosis in the general population with a self-report interview. J Nerv Ment Dis 1991;179(11):689-693.
16. Kendler KS, Gallagher TJ, Ableson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry 1996;53(11):1022-1031.
17. van Os J, Hanssen M, Bijl RV, Ravelli A. Strauss (1969) revisited: a psychosis continuum in the general population? Schizophr Res 2000;45(1-2):11-20.
18. Verdoux H, van Os J. Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res 2002;54(1-2):59-65.
19. Dutta R, Greene T, Addington J, McKenzie K, Phillips M, Murray RM. Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis. Schizophr Bull 2007;33(4):868-876.
20. Van Putten T, Crumpton E, Yale C. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry 1976;33(12):1443-1446.
21. Lysaker PH, Davis LW, Warman DM, Strasburger A, Beattie N. Stigma, social function and symptoms in schizophrenia and schizoaffective disorder: associations across 6 months. Psychiatry Res 2006;149(1-3):89-95.
22. Johns L, van Os J. The continuity of psychotic experiences in the general population. Clin Psychol Rev 2001;21(8):1125-1141.
23. Yung AR, Buckby JA, Cotton SM, Cosgrave EM, Killackey EJ, Stanford C, et al. Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. Schizophr Bull 2006;32(2):352-359.
24. McGlashan TH, Miller TJ, Woods SW. Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull 2001;27(4):563-570.
25. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65(1):28-37.
26. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59(10):921-928.
27. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163(5):790-799.
28. McGorry PD, Yung AR, Bechdolf A, Amminger P. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry 2008;65(1):25-27.
29. Cornblatt BA. The New York high risk project to the Hillside recognition and prevention (RAP) program. Am J Med Genet 2002;114(8):956-966.
30. Amminger GP, Schaefer MR, Papageorgiou K, et al. Omega-3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: a double-blind, randomized, placebo-controlled treatment study. Presented at the International Congress on Schizophrenia Research; 2007 March 28-April 1; Colorado Springs, CO.
31. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002;324(7342):886-891.
32. Smith R. In search of "non-disease" BMJ 2002;324(7342):883-885.
33. Baldessarini RJ. A plea for integrity of the bipolar disorder concept. Bipolar Disord 2000;2(1):3-7.
34. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007;64(9):1032-1039.
35. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord 2003;33(4):365-382.
36. Rutter M. Incidence of autism spectrum disorders: changes over time and their meaning. Acta Paediatr 2005;94(1):2-15.
37. Spitzer M. On defining delusions. Compr Psychiatry 1990;31(5):377-397.
38. Leeser J, O'Donohue W. What is a delusion? Epistemological dimensions. J Abnorm Psychol 1999;108(4):687-694.
39. Pierre JM. Faith or delusion? At the crossroads of religion and psychosis. J Psychiatr Pract 2001;7(3):163-172.
40. McKenna PJ. Disorders with overvalued ideas. Br J Psychiatry 1984;145:579-585.
41. Delespaul P, van Os J. Jaspers was right after all - delusions are distinct from normal beliefs. Against. Br J Psychiatry 2003;183:286.
42. Spitzer RL, First MB, Kendler KS, Stein DJ. The reliability of three definitions of bizarre delusions. Am J Psychiatry 1993;150(6):880-884.
43. Mojtabai R, Nicholson RA. Interrater reliability of ratings of delusions and bizarre delusions. Am J Psychiatry 1995;152(12):1804-1806.
44. Flaum M, Arndt S, Andreasen NC. The reliability of "bizarre" delusions. Comp Psychiatry 1991;32(1):59-65.
45. Bell V, Halligan PW, Ellis HD. Diagnosing delusions: a review of inter-rater reliability. Schizophr Res 2006;86(1-3):76-79.
46. Andrade C, Srinath S. True auditory hallucinations as a conversion symptom. Br J Psychiatry 1986;148:100-102.
47. Nakaya M. True auditory hallucinations as a conversion symptom. Psychopathology 1995;28(4):214-219.
48. Yee L, Korner AJ, McSwiggan S, Meares RA, Stevenson J. Persistent hallucinations in borderline personality disorder. Compr Psychiatry 2005;46(2):147-154.
49. Ellenson GE. Disturbances of perception in adult female incest survivors. Soc Casework 1986;67(7):149-160.
50. Heins T, Gray A, Tennant M. Persisting hallucinations following childhood sexual abuse. Aust N Z J Psychiatry 1990;24(4):561-565.
51. Baethge C. Grief hallucinations: true or pseudo? Serious or not? An inquiry into psychopathological and clinical features of a common phenomenon. Psychopathology 2002;35(5):296-302.
52. Hamner MB, Frueh BC, Ulmer HG, Arana GW. Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol Psychiatry 1999;45(7):846-852.
53. David D, Kutcher GS, Jackson EI, Mellman TA. Psychotic symptoms in combat-related posttraumatic stress disorder. J Clin Psychiatry 1999;60(1):29-32.
54. Taylor FK. On pseudo-hallucinations. Psychol Med 1981;11(2):265-271.
55. van der Zwaard R, Polak MA. Pseudohallucinations: a pseudoconcept? A review of the validity of the concept, related to associated symptomatology. Comp Psychiatry 2001;42(1):42-50.
56. Bentall RP. The illusion of reality: a review and integration of psychological research on hallucinations. Psychol Bull 1990;107(1):82-95.
57. Andreasen NC. Understanding schizophrenia: a silent spring? Am J Psychiatry 1998;155(12):1657-1659.
58. Andreasen NC. DSM and the death of phenomenology in America: an example of unintended consequences. Schizophr Bull 2007;33(1):108-112.
59. Bentall R. Madness explained: why we must reject the Kraepelinian paradigm and replace it with a 'complaint-oriented' approach to understanding mental illness. Med Hypotheses 2006;66(2):220-233.
60. Dikeos DG, Wickham H, McDonald C, Walshe M, Sigmundsson T, Bramon E, et al. Distribution of symptom dimensions across Kraepelinian divisions. Br J Psychiatry 2006;189:346-353.
61. Ketter TA, Wang PW, Becker OV, Nowakowska C, Yang Y. Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia? J Psychiatr Res 2004;38(1):47-61.
62. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994;182(4):193-204.
63. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26(1):119-136.
64. Keefe RS, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 2007;33(4):912-920.
65. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56(5):301-307.
66. Cannon TD. Clinical and genetic high-risk strategies in understanding vulnerability to psychosis. Schizophr Res 2005;79(1):35-44.
67. Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 2007;33(1):21-32.
68. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160(4):636-645.
69. Bearden CE, Freimer NB. Endophenotypes for psychiatric disorders: ready for primetime? Trends Genet 2006;22 (6):306-313.
70. Meehl PE. Schizotaxia revisited. Arch Gen Psychiatry 1989;46(10):935-944.
71. Tsuang MT, Stone WS, Faraone SV. Toward reformulating the diagnosis of schizophrenia. Am J Psychiatry 2000;157(7):1041-1050.
72. Andreasen NC, Paradiso S, O'Leary DS. "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr Bull 1998;24(2):203-218.
73. Andreasen NC. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. Arch Gen Psychiatry 1999;56(9):781-787.
74. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 2004;161(3):398-413.
75. Bromley E. Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia. Psychiatr Serv 2007;58(4):475-481.
76. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68(2-3):283-297.
77. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20(3):310-319.
78. Velligan DI, DiCocco M, Bow-Thomas CC, Cadle C, Glahn DC, Miller AL, et al. A brief cognitive assessment for use with schizophrenia patients in community clinics. Schizophr Res 2004;71(2-3):273-283.
79. Bratti IM, Marder SR, Keefe RSE, Bilder RM. A Brief Cognitive Assessment Tool for Schizophrenia (B-CATS): scale construction. Presented at the International Congress on Schizophrenia Research; 2007 March; Colorado Springs CO.
80. Millon T. Classification in psychopathology: rationale, alternatives, and standards. J Abnorm Psychol 1991;100(3):245-261.
81. Frances AJ, First MB, Widiger TA, Miele GM, Tilly SM, Davis WW, et al. An A to Z guide to DSM-IV conundrums. J Abnorm Psychol 1991;100(3):407-412.
82. Carson RC. Dilemmas in the pathway of the DSM-IV. J Abnorm Psychol 1991;100(3):302-307.
83. Morey LC. Classification of mental disorder as a collection of hypothetical constructs. J Abnorm Psychol 1991;100(3):289-293.
84. Levin T. Schizophrenia should be renamed to help educate patients and the public. Int J Soc Psychiatry 2006;52(4):324-331.
85. Lieberman JA, First MB. Renaming schizophrenia. BMJ 2007;334(7585):108.
86. Kingdon DG, Kinoshita Y, Naeem F, Swelam M, Hansen L, Vincent S, et al. Schizophrenia can and should be renamed. BMJ 2007;334(7587):221-222.